News & Events

Category: Press Releases 25 October 2021

Author

Dr Taubel discusses the future of new medicine development and first-in-human studies

In a recent article for PMLiVE and Pharmaceutical Market Europe, Dr Jorg Taubel, CEO of Richmond Pharmacology, outlines the future of new medicine development, influenced by the emergence of gene-based therapies and the reshaping of the way first-in-human clinical studies are delivered.

Read more ...

Category: Press Releases 6 July 2021

Author

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021. Richmond Pharmacology is delighted with the acknowledgement and features at 96 in the list of 200.

Read more ...

Category: Publications 19 May 2021

Author

Patient safety is paramount in drug trials

In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.

Read more ...

Category: COVID-19 21 April 2021

Author

Richmond Research Institute asks the question, 'Do post-COVID-19 patients need a second dose of vaccine?'

Richmond Research Institute is actively involved in COVID-19 symptoms testing for all staff and visitors who attempt entry to Richmond Pharmacology's London bridge clinical trial unit. The data accumulated throughout this period before and after vaccination has led to the following publication: 'Do post-COVID-19 patients need a second dose of vaccine?

Read more ...

Category: COVID-19 19 April 2021

Author

Do we still need challenge trials with COVID-19?

A response to a Human Challenge statement in the BMJ by Nir Eyal and colleagues.

Read more ...

Category: Press Releases 11 April 2021

Author

Accelero contributes tp CombiGene AB’s Gene Therapy Program for Epilepsy

Accelero is proud becoming a selected partner for the leading Nordic gene therapy company CombiGene AB (Lund) developing an AAV-based treatment targeting epilepsy.

Read more ...

Category: Publications 6 April 2021

Author

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.

Read more ...

Category: Publications 18 March 2021

Author

A new era for UK-Japanese scientific relations

As the UK and Japan embark on a new trade deal, there are aspirations of greater collaboration and investment between the two nations. Dr Jorg Taubel shares his thoughts on the future needs of the Japanese pharmaceutical market and how UK-Japanese scientific relations can support this in his recent article in the Pharmaceutical Market Europe and PMLive.

Read more ...

Category: Press Releases 19 February 2021

Author

Accelero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy

Accelero Bioanalytics GmbH (“Accelero”) is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy.

Read more ...

Category: Publications 19 January 2021

Author

Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.

Co-authored by Christian Wolf

Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L.

Neurology. 20219; 96:e376-e386. https://doi.org/10.1212/WNL.0000000000011275.